ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

ClinicalTrials.gov ID: NCT00605280

Public ClinicalTrials.gov record NCT00605280. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.

Study identification

NCT ID
NCT00605280
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
317 participants

Conditions and interventions

Interventions

  • Macugen Drug
  • Standard of Care Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2005
Primary completion
Oct 31, 2009
Completion
Jun 30, 2011
Last update posted
Nov 15, 2018

2005 – 2011

United States locations

U.S. sites
28
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85020
Pfizer Investigational Site Tucson Arizona 85704
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site Oakland California 94609
Pfizer Investigational Site Santa Ana California 92705
Pfizer Investigational Site Denver Colorado 80230
Pfizer Investigational Site Hamden Connecticut 06518
Pfizer Investigational Site Fort Lauderdale Florida 33334-4146
Pfizer Investigational Site Tampa Florida 33609
Pfizer Investigational Site Tampa Florida 33612
Pfizer Investigational Site Augusta Georgia 30909
Pfizer Investigational Site ‘Aiea Hawaii 96701
Pfizer Investigational Site Indianapolis Indiana 46280
Pfizer Investigational Site Wichita Kansas 67214
Pfizer Investigational Site Boston Massachusetts 02114
Pfizer Investigational Site Detroit Michigan 48201-1423
Pfizer Investigational Site Lynbrook New York 11563
Pfizer Investigational Site New York New York 10021
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Pittsburgh Pennsylvania 15213
Pfizer Investigational Site West Columbia South Carolina 29169
Pfizer Investigational Site Abilene Texas 79606
Pfizer Investigational Site Fort Worth Texas 76104
Pfizer Investigational Site Houston Texas 77002
Pfizer Investigational Site McAllen Texas 78503
Pfizer Investigational Site San Antonio Texas 78240
Pfizer Investigational Site Temple Texas 76508
Pfizer Investigational Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00605280, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 15, 2018 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00605280 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →